A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer's Disease (BenfoTeam)

The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease (AD).

In order to participate you must meet the following criteria:

• Are between 50 and 89 years of age.
• Have mild Alzheimer's disease (AD), mild cognitive impairment (MCI), or memory concerns noticed by another person.
• Have a study partner (such as a spouse, family member, or close friend) willing and able to attend study visits with you and to answer questions about you to study staff.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.